164 related articles for article (PubMed ID: 30381673)
1. Effects of Magnesium Oxide on the Serum Duloxetine Concentration and Antidepressant-Like Effects of Duloxetine in Rats.
Esumi S; Kitamura Y; Yokota-Kumasaki H; Ushio S; Yamada-Takemoto A; Nagai R; Ogawa A; Kawasaki Y; Sendo T
Biol Pharm Bull; 2018; 41(11):1727-1731. PubMed ID: 30381673
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine: a new selective and dual-acting antidepressant.
Bauer M; Möller HJ; Schneider E
Expert Opin Pharmacother; 2006 Mar; 7(4):421-7. PubMed ID: 16503814
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor.
Fan QY; Xue R; Li Y; Zhang TT; He XH; Fan SY; Li YF; Zhong BH; Zhang YZ; Li J
CNS Neurosci Ther; 2016 Aug; 22(8):700-6. PubMed ID: 27207183
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor.
Westanmo AD; Gayken J; Haight R
Am J Health Syst Pharm; 2005 Dec; 62(23):2481-90. PubMed ID: 16303903
[TBL] [Abstract][Full Text] [Related]
5. Behavioral and electroencephalographic properties of duloxetine (LY248686), a reuptake inhibitor of norepinephrine and serotonin, in mice and rats.
Katoh A; Eigyo M; Ishibashi C; Naitoh Y; Takeuchi M; Ibii N; Ikeda M; Matsushita A
J Pharmacol Exp Ther; 1995 Mar; 272(3):1067-75. PubMed ID: 7891317
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic profiles contribute to the differences in behavioral pharmacology of 071031B enantiomers as novel serotonin and norepinephrine reuptake inhibitors.
Xue R; Li Y; He XH; Jin ZL; Fan SY; Zhang TT; Li NM; Yuan L; Zheng AP; Zhong BH; Li YF; Zhang YZ
J Psychopharmacol; 2017 Mar; 31(3):377-386. PubMed ID: 28245750
[TBL] [Abstract][Full Text] [Related]
7. Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor.
Xue R; Jin ZL; Chen HX; Yuan L; He XH; Zhang YP; Meng YG; Xu JP; Zheng JQ; Zhong BH; Li YF; Zhang YZ
Eur Neuropsychopharmacol; 2013 Jul; 23(7):728-41. PubMed ID: 22748419
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of anti-obesity activity of duloxetine in comparison with sibutramine along with its anti-depressant activity: an experimental study in obese rats.
Chudasama HP; Bhatt PA
Can J Physiol Pharmacol; 2009 Nov; 87(11):900-7. PubMed ID: 19935897
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine and 8-OH-DPAT, but not fluoxetine, reduce depression-like behaviour in an animal model of chronic neuropathic pain.
Hu B; Doods H; Treede RD; Ceci A
Neurosci Lett; 2016 Apr; 619():162-7. PubMed ID: 26987721
[TBL] [Abstract][Full Text] [Related]
10. Effect of chronic administration of duloxetine on serotonin and norepinephrine transporter binding sites in rat brain.
Gould GG; Javors MA; Frazer A
Biol Psychiatry; 2007 Jan; 61(2):210-5. PubMed ID: 16650830
[TBL] [Abstract][Full Text] [Related]
11. Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression.
Berrocoso E; Mico JA
Int J Neuropsychopharmacol; 2009 Sep; 12(8):1033-44. PubMed ID: 19341511
[TBL] [Abstract][Full Text] [Related]
12. Antidepressant behavioral effects of duloxetine and amitriptyline in the rat forced swimming test.
Menezes HS; Bueno BB; Ciulla L; Schuh A; Luz Fde F; Alves RJ; Abegg MP; Cirino SL
Acta Cir Bras; 2008; 23(5):447-50. PubMed ID: 18797690
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects.
Turcotte JE; Debonnel G; de Montigny C; Hébert C; Blier P
Neuropsychopharmacology; 2001 May; 24(5):511-21. PubMed ID: 11282251
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine plasma level and antidepressant response.
De Donatis D; Florio V; Porcelli S; Saria A; Mercolini L; Serretti A; Conca A
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():127-132. PubMed ID: 30611837
[TBL] [Abstract][Full Text] [Related]
15. Does the new antidepressant duloxetine (Cymbalta) have any advantages over other antidepressant drugs?
Miller MC
Harv Ment Health Lett; 2004 Nov; 21(5):8. PubMed ID: 15556908
[No Abstract] [Full Text] [Related]
16. The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice.
Ren X; Xiong J; Liang L; Chen Y; Zhang G
Molecules; 2022 Apr; 27(9):. PubMed ID: 35566106
[TBL] [Abstract][Full Text] [Related]
17. Serotonin and Norepinephrine Reuptake Inhibitors.
Shelton RC
Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
[TBL] [Abstract][Full Text] [Related]
18. Dopamine D(1) and D(2) receptor agonism enhances antinociception mediated by the serotonin and noradrenaline reuptake inhibitor duloxetine in the rat formalin test.
Munro G
Eur J Pharmacol; 2007 Dec; 575(1-3):66-74. PubMed ID: 17725928
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
[TBL] [Abstract][Full Text] [Related]
20. Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects.
Chappell JC; Eisenhofer G; Owens MJ; Haber H; Lachno DR; Dean RA; Knadler MP; Nemeroff CB; Mitchell MI; Detke MJ; Iyengar S; Pangallo B; Lobo ED
J Clin Psychopharmacol; 2014 Feb; 34(1):9-16. PubMed ID: 24346757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
